Download PDF
Semin Neurol 2022; 42(06): 716-722
DOI: 10.1055/a-1985-0230
Review Article

Challenging Neuromuscular Disease Cases

Cynthia Bodkin
1   Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana
,
Adam Comer
1   Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana
,
Marcia Felker
2   Division of Pediatric Neurology, Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana
,
Laurie Gutmann
1   Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana
,
Karra A. Jones
3   Department of Pathology, Duke University Medical Center, Durham, North Carolina
,
John Kincaid
1   Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana
,
Katelyn K. Payne
1   Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana
4   Department of Medical Genetics and Genomics, Indiana University School of Medicine, Indianapolis, Indiana
,
Blair Skinner
1   Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

The diagnosis of neuromuscular disorders requires a thorough history including family history and examination, with the next steps broadened now beyond electromyography and neuropathology to include genetic testing. The challenge in diagnosis can often be putting all the information together. With advances in genetic testing, some diagnoses that adult patients may have received as children deserve a second look and may result in diagnoses better defined or alternative diagnoses made. Clearly defining or redefining a diagnosis can result in understanding of potential other systems involved, prognosis, or potential treatments. This article presents several cases and approach to diagnosis as well as potential treatment and prognostic concerns, including seipinopathy, congenital myasthenic syndrome, central core myopathy, and myotonic dystrophy type 2.

Keywords

myopathy - congenital myasthenic syndrome - myotonic dystrophy - seipinopathy


Publication History

Accepted Manuscript online:
23 November 2022

Article published online:
29 December 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Ito D, Suzuki N. Seipinopathy: a novel endoplasmic reticulum stress-associated disease. Brain 2009; 132 (Pt 1): 8-15
    CrossrefPubMedGoogle Scholar
  • 2 Rickman OJ, Baple EL, Crosby AH. Lipid metabolic pathways converge in motor neuron degenerative diseases. Brain 2020; 143 (04) 1073-1087
    CrossrefPubMedGoogle Scholar
  • 3 Choudhary V, Schneiter R. A unique junctional interface at contact sites between the endoplasmic reticulum and lipid droplets. Front Cell Dev Biol 2021; 9: 650186
    CrossrefPubMedGoogle Scholar
  • 4 Ito D. BSCL2-Related Neurologic Disorders/Seipinopathy. GeneReviews® Internet. 2005 Accessed October 31, 2021 at: https://pubmed.ncbi.nlm.nih.gov/20301484/
    PubMedGoogle Scholar
  • 5 Windpassinger C, Auer-Grumbach M, Irobi J. et al. Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome. Nat Genet 2004; 36 (03) 271-276
    CrossrefPubMedGoogle Scholar
  • 6 Auer-Grumbach M, Schlotter-Weigel B, Lochmüller H. et al; Austrian Peripheral Neuropathy Study Group. Phenotypes of the N88S Berardinelli-Seip congenital lipodystrophy 2 mutation. Ann Neurol 2005; 57 (03) 415-424
    CrossrefPubMedGoogle Scholar
  • 7 Irobi J, Van den Bergh P, Merlini L. et al. The phenotype of motor neuropathies associated with BSCL2 mutations is broader than Silver syndrome and distal HMN type V. Brain 2004; 127 (Pt 9): 2124-2130
    CrossrefPubMedGoogle Scholar
  • 8 Berardinelli W. An undiagnosed endocrinometabolic syndrome: report of 2 cases. J Clin Endocrinol Metab 1954; 14 (02) 193-204
    CrossrefPubMedGoogle Scholar
  • 9 Seip M. Lipodystrophy and gigantism with associated endocrine manifestations. A new diencephalic syndrome?. Acta Paediatr (Stockh) 1959; 48: 555-574
    PubMedGoogle Scholar
  • 10 Winder TL, Tan CA, Klemm S. et al. Clinical utility of multigene analysis in over 25,000 patients with neuromuscular disorders. Neurol Genet 2020; 6 (02) e412
    CrossrefPubMedGoogle Scholar
  • 11 North K. Congenital myopathies. In: Engel AG, Franzini-Armstrong C, eds. Myology: Basic and Clinical. 3rd ed. New York, NY: McGraw-Hill; 2004: 1502-1503
    Google Scholar
  • 12 Bartholomeus MG, Gabreëls FJ, ter Laak HJ, van Engelen BG. Congenital fibre type disproportion a time-locked diagnosis: a clinical and morphological follow-up study. Clin Neurol Neurosurg 2000; 102 (02) 97-101
    CrossrefPubMedGoogle Scholar
  • 13 Sobrido MJ, Fernández JM, Fontoira E. et al. Autosomal dominant congenital fibre type disproportion: a clinicopathological and imaging study of a large family. Brain 2005; 128 (Pt 7): 1716-1727
    CrossrefPubMedGoogle Scholar
  • 14 Engel AG, Ohno K, Sine SM. Congenital myasthenic syndromes. In: Engel AG, Franzini-Armstrong C, eds. Myology: Basic and Clinical. 3rd ed. New York, NY: McGraw-Hill; 2004: 1833-1835
    Google Scholar
  • 15 Burke G, Cossins J, Maxwell S. et al. Rapsyn mutations in hereditary myasthenia: distinct early- and late-onset phenotypes. Neurology 2003; 61 (06) 826-828
    CrossrefPubMedGoogle Scholar
  • 16 Engel AG, Shen XM, Selcen D, Sine SM. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol 2015; 14 (04) 420-434
    CrossrefPubMedGoogle Scholar
  • 17 Dlamini N, Voermans NC, Lillis S. et al. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis. Neuromuscul Disord 2013; 23 (07) 540-548
    CrossrefPubMedGoogle Scholar
  • 18 Klein A, Lillis S, Munteanu I. et al. Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies. Hum Mutat 2012; 33 (06) 981-988
    CrossrefPubMedGoogle Scholar
  • 19 Wu S, Ibarra MC, Malicdan MC. et al. Central core disease is due to RYR1 mutations in more than 90% of patients. Brain 2006; 129 (Pt 6): 1470-1480
    CrossrefPubMedGoogle Scholar
  • 20 Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P. Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 2006; 27 (10) 977-989
    CrossrefPubMedGoogle Scholar
  • 21 Hopkins PM, Rüffert H, Snoeck MM. et al; European Malignant Hyperthermia Group. European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. Br J Anaesth 2015; 115 (04) 531-539
    CrossrefPubMedGoogle Scholar
  • 22 Paganoni S, Amato A. Electrodiagnostic evaluation of myopathies. Phys Med Rehabil Clin N Am 2013; 24 (01) 193-207
    CrossrefPubMedGoogle Scholar
  • 23 Meola G. Myotonic dystrophy type 2: the 2020 update. Acta Myol 2020; 39 (04) 222-234
    PubMedGoogle Scholar
  • 24 Liquori CL, Ricker K, Moseley ML. et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001; 293 (5531): 864-867
    CrossrefPubMedGoogle Scholar
  • 25 Thornton CA, Griggs RC, Moxley III RT. Myotonic dystrophy with no trinucleotide repeat expansion. Ann Neurol 1994; 35 (03) 269-272
    CrossrefPubMedGoogle Scholar
  • 26 Schoser BG, Schneider-Gold C, Kress W. et al. Muscle pathology in 57 patients with myotonic dystrophy type 2. Muscle Nerve 2004; 29 (02) 275-281
    CrossrefPubMedGoogle Scholar
  • 27 Schoser B, Montagnese F, Bassez G. et al; Myotonic Dystrophy Foundation. Consensus-based care recommendations for adults with myotonic dystrophy type 2. Neurol Clin Pract 2019; 9 (04) 343-353
    CrossrefPubMedGoogle Scholar